dna
vaccin
present
new
simpl
concept
vaccin
strategi
antigenencod
bacteri
plasmid
produc
immun
respons
inocul
suitabl
host
garmori
et
al
josefsberg
barri
potenti
applic
plasmid
dna
gene
therapi
approach
matter
debat
long
time
wolff
et
al
dna
vaccin
elicit
neutral
antibodi
induc
helper
cell
respons
phenotyp
cytotox
tlymphocyt
respons
donnelli
et
al
immun
carri
via
ingest
purifi
plasmid
host
cell
cell
recognit
antigenpres
cell
apc
depend
express
spectrum
peptid
bound
class
ii
major
histocompat
complex
mhc
molecul
subsequ
protein
express
result
present
normal
modifi
form
protein
immun
system
world
organ
anim
health
oie
dna
vaccin
advantag
vaccin
first
advantag
dna
vaccin
promot
humor
immun
respons
cellmedi
immun
respons
two
respons
critic
also
known
dna
vaccin
induc
longterm
immun
mani
diseas
becom
requir
vaccin
efficaci
dna
vaccin
easi
produc
purifi
enabl
product
evalu
new
dna
vaccin
anim
model
within
month
anoth
advantag
long
shelf
life
dna
vaccin
capabl
transport
need
cold
chain
variou
studi
includ
human
show
reliabl
dna
vaccin
bagarazzi
et
al
kim
et
al
dna
vaccin
prove
rodent
effici
studi
dna
vaccin
continu
even
outbr
speci
carvalho
et
al
red
weiner
current
four
dna
vaccin
licens
veterinari
use
one
swine
australia
growth
hormon
releas
hormon
infecti
hematopoiet
necrosi
viru
salmon
canada
other
west
nile
viru
wnv
hors
melanoma
dog
usa
kutzler
weiner
optim
variou
level
requir
larg
anim
speci
succeed
higher
influenc
includ
vector
modif
dna
submiss
path
procedur
addit
adjuv
antigen
target
apc
inadequ
benefit
dna
vaccin
larg
anim
like
caus
ineffect
transfect
administ
plasmid
ineffici
vaccin
interfer
suffici
induct
develop
immun
rao
et
al
protect
immun
accomplish
dna
vaccin
pestiviru
glycoprotein
major
protect
antigen
bovin
viral
diarrhea
viru
bvdv
cattl
classic
swine
fever
viru
csfv
pig
poultri
possibl
dna
vaccin
flu
use
plasmid
code
hemagglutinin
ha
main
target
neutral
antibodi
alon
mixtur
nucleoprotein
np
primari
target
cytotox
lymphocyt
ctl
respons
establish
sever
studi
brun
et
al
vaccin
induc
immunogen
enabl
protect
plasmid
dna
bhv
mice
cox
et
al
malaria
mice
mor
et
al
sedegah
et
al
hepat
b
chimpanze
davi
et
al
human
immunodefici
viru
rhesu
monkey
lekuti
et
al
influenza
viru
ferret
donnelli
et
al
mycobacterium
tuberculosi
mice
lowri
et
al
lynch
et
al
genit
herp
simplex
viru
guinea
pig
bourn
et
al
apart
trial
recent
dna
vaccin
enter
phase
human
clinic
trial
protect
hiv
malaria
influenza
dna
vaccin
mani
diseas
evalu
experiment
studi
anim
model
realtim
pcr
histopatholog
examin
confirm
low
viral
dna
load
mild
histopatholog
lesion
appear
mice
follow
viru
challeng
show
protect
immun
porcin
circoviru
vaccin
dna
subunit
vaccin
mice
shen
et
al
bovin
leukemia
viru
blv
envelop
gene
encod
extracellular
transmembran
glycoprotein
clone
vector
human
cytomegaloviru
cmv
intermedi
earli
promot
dna
vaccin
construct
cellular
immun
respons
promot
intramuscular
administr
plasmid
vector
done
brillowska
et
al
anoth
studi
blv
transactiv
tax
clone
mammalian
cell
express
plasmid
show
type
immun
respons
induc
tax
dna
vaccin
inhibit
blv
propag
vaccin
sheep
earli
phase
infect
usui
et
al
gogev
et
al
show
efficaci
bovin
herpesviru
dna
vaccin
cattl
studi
bovin
herpesviru
glycoprotein
c
use
antigen
calv
administr
recombin
andor
composit
increas
bovin
herpesviru
neutral
antibodi
respons
present
protect
challeng
iowa
strain
gogev
et
al
anoth
research
made
bovin
herpesviru
dna
vaccin
use
vector
express
glycoprotein
gd
pontarollo
et
al
vector
pmasia
express
fulllength
gb
huang
et
al
schrijver
et
al
prepar
dna
vaccin
ge
gene
chang
gene
encod
g
protein
bovin
respiratori
syncyti
viru
brsv
bovin
herpesviru
vector
result
studi
g
protein
brsv
stimul
consider
protect
brsv
infect
cattl
vaccin
protect
power
subsequ
brsv
bovin
herpesviru
infect
schrijver
et
al
vaccin
also
poultri
flock
manag
import
vaccin
research
current
avail
commerci
vaccin
number
increas
daybyday
sakaguchi
et
al
gener
plasmid
vector
express
newcastl
diseas
viru
f
protein
ndvf
control
human
cytomegaloviru
immedi
earli
enhanc
chicken
betaactin
gene
promot
result
exhibit
dna
vaccin
use
newcastl
diseas
sakaguchi
et
al
park
et
al
gener
chimer
avian
influenza
viru
aiv
viru
express
ectodomain
hemagglutininneuraminidas
gene
place
neuraminidas
protein
aiv
singl
vaccin
chicken
improv
vaccin
prototyp
viru
induc
strong
immun
highli
pathogen
aiv
newcastl
diseas
viru
park
et
al
park
et
al
propos
chimer
construct
develop
conveni
inexpens
effect
immun
newcastl
diseas
avian
influenza
poultri
park
et
al
dna
vaccin
evalu
protect
viral
bacteri
diseas
also
protozoan
diseas
associ
abort
cattl
variou
experiment
studi
exist
protozoan
diseas
one
recombin
dna
vaccin
protein
neospora
caninum
mice
canna
et
al
result
suggest
highli
signific
protect
effect
combin
dna
base
recombin
antigen
vaccin
base
cerebr
neosporosi
mice
canna
et
al
avail
recombin
dna
technolog
knowledg
specif
virul
factor
pathogen
facilit
use
genedelet
pathogen
vaccin
genedelet
pathogen
pathogen
virul
decreas
without
affect
immunogen
genedelet
agent
caus
diseas
howev
immunogen
featur
wildtyp
agent
must
genet
stabl
easili
reproduc
easi
manipul
organ
vaccin
strain
bacteri
pathogen
creat
provid
better
protect
inactiv
kill
vaccin
genedelet
vaccin
technolog
also
use
marker
vaccin
use
differenti
infect
anim
vaccin
anim
genedelet
salmonella
enterica
serovar
typhimurium
serovar
enteritidi
licens
use
poultri
babu
et
al
meeusen
et
al
pig
pseudorabi
viru
marker
vaccin
gener
doubl
gene
ge
tk
delet
viru
ferrari
et
al
meeusen
et
al
also
cattl
viru
marker
vaccin
produc
ge
delet
meeusen
et
al
van
oirschot
et
al
anoth
genedelet
vaacin
streptococcu
equi
hors
streptococcu
equi
vaccin
gener
aroa
gene
delet
licens
jakob
et
al
meeusen
et
al
widjojoatmodjo
et
al
show
possibl
gener
delet
mutant
virus
lack
entir
ern
csfv
mutant
abil
develop
compet
cell
line
safe
vaccin
mutant
virus
stimul
power
immuno
respons
immun
respons
compris
without
gener
new
viral
progeni
widjojoatmodjo
et
al
relat
strategi
use
build
sever
chimaera
exchang
ern
protein
attenu
c
strain
csfv
antigen
relat
pestivirus
van
gennip
et
al
use
convent
vaccin
infecti
bovin
rhinotrach
ibr
seem
consequenc
decreas
preval
diseas
marker
vaccin
compris
mutant
delet
glycoprotein
includ
gene
nonessenti
marker
vaccin
use
diagnost
test
separ
cattl
infect
vaccin
marker
vaccin
van
oirschot
et
al
one
bovili
ibr
marker
cattl
distribut
intervet
viruslik
particl
vlp
involv
one
recombin
protein
supramolecular
structur
particl
nm
size
icosahedr
rodlik
structur
jen
bachmann
vlp
vaccin
antigen
increas
immunogen
vaccin
via
particul
structur
offer
advantag
vpl
brun
et
al
vlp
use
vaccin
carrier
genet
modifi
antigen
studi
two
decad
hepat
b
viru
zuckerman
human
papillomaviru
stanley
vaccin
commerci
present
studi
underway
develop
vaccin
bluetongu
viru
rotaviru
parvoviru
veterinari
applic
vlp
mani
advantag
vaccin
high
safeti
profil
featur
also
similar
bacteri
viral
structur
capabl
largescal
product
advantag
possibl
combin
vaccin
adjuv
vlp
induc
strong
rapid
antibodi
respons
induct
tindepend
igm
respons
activ
b
cell
activ
via
b
cell
receptor
activ
via
vaccin
antigen
cross
link
bachmann
zinkernagel
brun
et
al
thyagarajan
et
al
vlp
also
process
exogen
antigen
present
mhc
class
ii
molecul
helper
cell
activ
pejawargaddi
et
al
win
et
al
thu
complement
system
activ
result
elev
phagocytosi
strong
immun
respons
enhanc
uptak
particul
structur
vlp
apc
demonstr
particul
antigen
much
effici
solubl
antigen
induc
immun
respons
lenz
et
al
cpg
odn
singlestrand
rna
success
combin
vlp
molecular
adjuv
dendrit
cell
stimul
certain
vlp
directli
exampl
papillomaviru
vlp
bovin
rotaviru
viru
vlp
highli
immunogen
elicit
protect
infect
redmond
et
al
exampl
vaccin
vlp
includ
hepat
b
surfac
antigen
vlp
hbsagvlp
hiv
dv
dengu
viru
noroviru
influenza
vlp
mani
anim
viru
vlp
deriv
immunogen
exampl
vlp
includ
ndv
porcin
parvoviru
ppv
rift
valley
fever
viru
rvfv
vlp
porcin
circoviru
vlp
aiv
bluetongu
viru
btv
vlp
jeoung
et
al
lynch
et
al
mani
vlp
induc
neutral
antibodi
protect
anim
model
roy
show
immun
protect
effect
high
immunogen
vlp
produc
bluetongu
viru
sheep
roy
stewart
et
al
demonstr
bluetongu
viru
vlp
safe
highli
effect
immunogen
sheep
reduc
postchalleng
viraemia
level
threshold
molecular
detect
limit
stewart
et
al
vlp
vaccin
current
avail
veterinari
field
anticip
vlp
vaccin
develop
use
field
near
futur
two
technolog
use
vaccin
product
offer
use
antigen
structur
induct
satisfactori
immun
respons
includ
liveattenu
inactiv
subunit
vaccin
liveattenu
vaccin
effect
howev
alway
possess
risk
major
advantag
inactiv
subunit
vaccin
safe
use
day
schultz
despit
advantag
limit
efficaci
limit
immun
limit
use
vaccin
dna
vaccin
offer
new
strong
approach
subunit
vaccin
den
hurk
et
al
subunit
vaccin
consist
semipur
purifi
protein
subunit
vaccin
produc
recombin
dna
technolog
sinc
commerci
avail
sinc
cohen
rhode
et
al
ulmer
et
al
sinc
first
bacteri
genom
sequenc
genom
sequenc
obtain
number
bacteri
viral
parasit
genom
howev
develop
bioinformat
resourc
tool
requir
analyz
genom
allow
identif
surfac
expos
antigen
specif
b
cell
epitop
subunit
antigen
product
obtain
biochem
dna
technolog
biochem
techniqu
use
product
subunit
vaccin
use
recombin
express
appropri
shown
fimbria
bacteria
campylobact
jejuni
glycosyl
mani
surfac
protein
therefor
best
produc
c
jejuni
rather
heterolog
express
system
also
appli
escherichia
coli
show
similar
featur
wacker
et
al
escherichia
coli
vaccin
calf
scour
could
one
best
exampl
subunit
vaccin
acr
et
al
anoth
exampl
baculoviru
use
vaccin
porcin
circoviru
type
faching
et
al
subunit
vaccin
offer
advantag
first
stimul
strong
humor
cellmedi
immun
respons
consider
safe
combin
subunit
vaccin
occas
subunit
vaccin
requir
adjuv
induc
better
immun
respons
glycoprotein
product
costli
subunit
vaccin
subunit
vaccin
compat
diva
strategi
bovin
herp
viru
glycoprotein
gd
success
use
subunit
vaccin
although
immun
gd
proven
partial
effect
reduc
preval
viru
field
thu
limit
use
harland
et
al
van
drunen
littelvan
den
hurk
et
al
anoth
research
bovin
herp
viru
vaccin
show
subunit
gd
tgdvaccin
calv
shed
significantli
lower
amount
viru
placebo
kill
virusimmun
group
throughout
followup
period
gd
tgd
subunit
vaccin
vaccin
group
one
eight
anim
shed
viru
van
drunen
littelvan
den
hurk
et
al
licens
porcin
circoviru
vaccin
report
characterist
inactiv
baculoviru
express
protein
pig
intervet
brand
name
blanchard
et
al
anoth
licens
porcin
circoviru
vaccin
suvaxyn
fort
dodg
use
inactiv
chimera
fenaux
et
al
licens
vaccin
pseudorabi
viru
pig
suvaxyn
aujeszki
distribut
fort
dodg
characterist
vaccin
ige
thymidin
kinasedelet
marker
vaccin
ferrari
et
al
csfv
infect
continu
subject
studi
explor
success
effect
vaccin
vaccin
commerci
avail
first
one
intervet
bayer
baculoviru
recombin
protein
use
vaccin
compani
van
aarl
mani
subunit
vaccin
test
commerci
avail
includ
vaccin
respiratori
enter
virus
bvdv
brsv
rotaviru
coronaviru
success
bacteri
subunit
vaccin
viral
subunit
vaccin
result
recombin
convent
product
cost
recombin
vaccin
prepar
respiratori
system
pathogen
commerci
avail
includ
vaccin
mannheimia
haemolytica
actinobacillu
pleuropneumonia
vaccin
formul
leucotoxin
transferrinbind
protein
bacteria
vaccin
prepar
atroph
rhiniti
formul
nontox
pasteurella
multocida
dermonecrot
toxin
toxin
produc
togeth
genet
modifi
e
coli
strain
convent
b
bronchiseptica
bacterin
shewen
wilki
liveattenu
vaccin
classic
swine
flu
csf
rapid
onset
immun
effect
prevent
transmiss
infect
van
oirschot
disadvantag
vaccin
pig
differenti
infect
pig
vaccin
studi
follow
diva
ongo
classic
swine
flu
csf
vaccin
develop
mani
viral
diseas
occur
farm
anim
howev
vaccin
interfer
surveil
diseas
serolog
test
individu
countri
may
lose
free
infect
statu
promin
exampl
fmd
occur
cattl
mani
vaccin
avail
use
fmd
vaccin
use
diseas
control
doel
howev
use
fmd
free
countri
marker
vaccin
develop
use
diagnost
test
delet
certain
gene
pathogen
divadifferenti
infect
vaccin
anim
antibodi
produc
delet
gene
pathogen
therefor
possibl
differenti
vaccin
infect
anim
van
oirschot
mani
diva
vaccin
diagnost
test
kit
vaccin
develop
diva
vaccin
use
develop
mani
diseas
import
farm
anim
ibr
pseudorabi
classic
swine
fever
csf
fmd
origin
term
appli
genedelet
marker
vaccin
larg
dna
virus
use
vaccin
specif
serolog
test
also
appli
subunit
vaccin
heterolog
vaccin
kill
whole
pathogen
vaccin
highli
purifi
fmd
vaccin
use
conjunct
nonstructur
proteinbas
serolog
test
ahren
et
al
capua
et
al
de
smit
et
al
sorensen
et
al
numer
strategi
use
develop
diva
vaccin
csfv
variabl
achiev
regard
capac
reduc
viral
replic
anim
avoid
transplacent
transmiss
viru
vaccin
includ
fulllength
csfv
glycoprotein
fraction
mainli
hammond
et
al
glycoprotein
e
ge
delet
diva
vaccin
ibr
develop
european
convent
methodolog
van
oirschot
et
al
ge
protein
gene
requir
viral
replic
ibr
howev
gene
play
import
role
spread
across
host
cell
elisa
techniqu
pcr
amplif
develop
diagnost
test
gedelet
diva
vaccin
perrin
et
al
schynt
et
al
diva
strategi
develop
delet
ge
gene
also
use
aujeszki
diseas
pensaert
et
al
diva
vaccin
develop
classic
swine
flu
csf
produc
viral
envelop
glycoprotein
protein
baculovirusinsect
cell
system
formul
adjuv
elisa
diagnost
kit
also
produc
diva
vaccin
moormann
et
al
van
aarl
usual
diva
vaccin
disadvantag
compar
convent
live
attenu
vaccin
beer
et
al
host
bodi
must
expos
one
epitop
pathogen
order
induc
strong
immun
respons
purpos
studi
focus
develop
vaccin
combin
capsid
protein
grubman
mani
diseas
diva
vaccin
need
surveil
epidemiolog
data
particularli
includ
pest
de
petit
rumin
viru
bluetongu
viru
cattl
ndv
aiv
poultri
bovin
viral
diarrhea
viru
